Eli Lilly and Company (lly)

LLY — Company Overview

Investors tracking LLY follow a Drug Manufacturers - General name listed on NYQ within Healthcare.

LLY — Business Description

The business profile of Eli Lilly and Company (LLY) reflects its role in Drug Manufacturers - General. Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and h…

Official website: https://www.lilly.com.

LLY — Investment Thesis

Eli Lilly and Company (LLY) attracts investors weighing Drug Manufacturers - General fundamentals against current market pricing.

• Revenue is expanding at roughly 47.7% year-over-year (public data).
• Trailing P/E of 38.57× implies elevated growth expectations at the current price.
• Forward P/E (24.31×) is below trailing P/E — earnings may be expected to improve.
• Dividend yield near 0.6% adds an income component to total return.
• Equity market capitalization is approximately $1.03T.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

LLY — Financial Health

LLY financial profile reflects operating efficiency and capital structure using available market fundamentals.

Profit margin of 33.5% indicates solid bottom-line conversion. Positive free cash flow of $11.07B supports balance-sheet flexibility. Debt-to-equity of 162.07 warrants monitoring in a higher-rate environment.

LLY — Growth Outlook

Growth outlook for Eli Lilly and Company (LLY) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.

• Revenue growth of 47.7% indicates strong top-line momentum.
• Earnings growth of 26.2% year-over-year supports improving profitability.
• Price is 11.0% below the 52-week high.

LLY — Competitive Position

Eli Lilly and Company (LLY) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Drug Manufacturers - General.
• Market capitalization of $1.03T places LLY among mega-cap peers.
• Gross margin near 83.4% may reflect pricing power or favorable mix.

LLY — Summary

Eli Lilly and Company (LLY) is a mega-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $1150.99 with market cap $1.03T. Trailing P/E 38.57×. Revenue grew 47.7% year-over-year per public data. Notable strengths include revenue growth of 47.7% year-over-year. Key watch items include elevated trailing p/e (38.57×) limits valuation margin of safety. Review free estimates and earnings pages for LLY; upgrade for institutional ownership and live headlines.